Luteolin, a non-selective competitive inhibitor of phosphodiesterases 1-5, displaced [3H]-rolipram from high-affinity rolipram binding sites and reversed xylazine/ketamine-induced anesthesia

European Journal of Pharmacology

Volumn 627, Issue 1-3, 2010, Pages 269-275

  Yu, Ming Chih ^a   Chen, Jun Hao ^b   Lai, Chi Yin ^b   Han, Cheng Ying ^b   Ko, Wun Chang ^b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Emesis; High affinity rolipram binding site; Luteolin; PDE4H PDE4L ratio; Phosphodiesterase (PDE) 1 5 inhibitor; Xylazine ketamine induced anesthesia

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; ALPHA 2 ADRENERGIC RECEPTOR; KETAMINE; LUTEOLIN; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE V; ROLIPRAM; SPLEEN EXONUCLEASE; TRITIUM; XYLAZINE;

ANESTHESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CELL; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG BINDING SITE; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FERRET; GUINEA PIG; MALE; MOUSE; NAUSEA; NERVE CELL MEMBRANE; NONHUMAN; PRIORITY JOURNAL; STOMACH SECRETION; VOMITING;

ANESTHESIA; ANIMALS; BINDING, COMPETITIVE; FEMALE; GUINEA PIGS; KETAMINE; LUTEOLIN; MALE; MICE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PROTEIN BINDING; ROLIPRAM; TRITIUM; XYLAZINE;

EID: 73449123347     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.10.031     Document Type: Article

References (41)

1. Ahn H.S., Crim W., Romano M., Sybertz E., and Pitts B. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem. Pharmacol. 38 (1989) 3331-3339
2. 3H]-rolipram binding. Biochem. Pharmacol. 51 (1996) 949-956
3. Bender A.T., and Beavo J.A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 58 (2006) 488-520
4. Bischoff E. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int. J. Impot. Res. 16 Suppl 1 (2004) S11-S14
5. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72 (1976) 248-254
6. 3H]-rolipram binding in guinea pig tissues. Invest. New Drugs 26 (2008) 417-424
7. Cherry J.A., Thompson B.E., and Pho V. Diazepam and rolipram differentially inhibit cyclic AMP-specific phosphodiesterases PDE4A1 and PDE4B3 in the mouse. Biochim. Biophys. Acta 1518 (2001) 27-35
8. Coleta M., Campos M.G., Cotrim M.D., Lima T.C., and Cunha A.P. Assessment of luteolin (3′, 4′, 5, 7-tetrahydroxyflavone) neuropharmacological activity. Behav. Brain Res. 189 (2008) 75-82
9. Das M., Ram A., and Ghosh B. Luteolin alleviates bronchoconstriction and airway hyperreactivity in ovalbumin sensitized mice. Inflamm. Res. 52 (2003) 101-106
10. de Boer J., Philpott A.J., van Amsterdam R.G., Shahid M., Zaagsma J., and Nicholson C.D. Human bronchial cyclic nucleotide phosphodiesterase isoenzymes: biochemical and pharmacological analysis using selective inhibitors. Br. J. Pharmacol. 106 (1992) 1028-1034
11. Draheim R., Egerland U., and Rundfeldt C. Anti-inflammatory potential of the selective phosphodiesterase 4 inhibitor N-(3, 5-dichloro-pyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), in human cell preparations. J. Pharmacol. Exp. Ther. 308 (2004) 555-563
12. Giembycz M.A. Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?. Drugs 59 (2000) 193-212
13. Gillespie P.G., and Beavo J.A. Inhibition and stimulation of photoreceptor phosphodiesterases by dipyridamole and M&B 22, 948. Mol. Pharmacol. 36 (1989) 773-781
14. Guzman-Gutierrez S.L., and Navarrete A. Pharmacological exploration of the sedative mechanism of hesperidin identified as the active principle of Citrus sinensis flowers. Planta Med. 75 (2009) 295-301
15. Harrison S.A., Reifsnyder D.H., Gallis B., Cadd G.G., and Beavo J.A. Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs. Mol. Pharmacol. 29 (1986) 506-514
16. Hatzelmann A., and Schudt C. Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. J. Pharmacol. Exp. Ther. 297 (2001) 267-279
17. Hertog M.G.L., Hollman P.C.H., and Katan M.B. Content of potentially anticarcinogenic flavonoids of 28 vegetables and 9 fruits commonlly consumed in the Netherlands. J. Agric. Food Chemistry 40 (1992) 2379-2383
18. Kawai M., Hirano T., Higa S., Arimitsu J., Maruta M., Kuwahara Y., Ohkawara T., Hagihara K., Yamadori T., Shima Y., Ogata A., Kawase I., and Tanaka T. Flavonoids and related compounds as anti-allergic substances. Allergol. Int. 56 (2007) 113-123
19. Kim J.H., Jin Y.R., Park B.S., Kim T.J., Kim S.Y., Lim Y., Hong J.T., Yoo H.S., and Yun Y.P. Luteolin prevents PDGF-BB-induced proliferation of vascular smooth muscle cells by inhibition of PDGF beta-receptor phosphorylation. Biochem. Pharmacol. 69 (2005) 1715-1721
20. Ko W.C., Chen M.C., Wang S.H., Lai Y.H., Chen J.H., and Lin C.N. 3-O-methylquercetin more selectively inhibits phosphodiesterase subtype 3. Planta Med. 69 (2003) 310-315
21. Ko W.C., Shih C.M., Lai Y.H., Chen J.H., and Huang H.L. Inhibitory effects of flavonoids on phosphodiesterase isozymes from guinea pig and their structure-activity relationships. Biochem. Pharmacol. 68 (2004) 2087-2094
22. Kotanidou A., Xagorari A., Bagli E., Kitsanta P., Fotsis T., Papapetropoulos A., and Roussos C. Luteolin reduces lipopolysaccharide-induced lethal toxicity and expression of proinflammatory molecules in mice. Am. J. Respir. Crit. Care Med. 165 (2002) 818-823
23. Lee M.E., Markowitz J., Lee J.O., and Lee H. Crystal structure of phosphodiesterase 4D and inhibitor complex (1). FEBS Lett. 530 (2002) 53-58
24. Lipworth B.J. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365 (2005) 167-175
25. Menniti F.S., Faraci W.S., and Schmidt C.J. Phosphodiesterases in the CNS: targets for drug development. Nat. Rev. Drug Discov. 5 (2006) 660-670
26. Murphy A.W., and Platts-Mills T.A.E. Drug used in asthma and obstructive lung disease. In: Brody T.M., Larner J., and Minneman K.P. (Eds). Human Pharmacology,Molecular to Clinical (1998), Mosby, St. Louis, MO 797-809
27. Podzuweit T., Muller P., and Nennstiel A. Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3-nonyl) adenine. Cell. Signal 7 (1995) 733-738
28. Reeves M.L., Leigh B.K., and England P.J. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle, implications for the mechanism of action of selective phosphodiesterase inhibitors. Biochem. J. 241 (1987) 535-541
29. Robichaud A., Savoie C., Stamatiou P.B., Lachance N., Jolicoeur P., Rasori R., and Chan C.C. Assessing the emetic potential of PDE4 inhibitors in rats. Br. J. Pharmacol. 135 (2002) 113-118
30. Robichaud A., Savoie C., Stamatiou P.B., Tattersall F.D., and Chan C.C. PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway. Neuropharmacology 40 (2001) 262-269
31. 2-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J. Clin. Invest. 110 (2002) 1045-1052
32. Rybalkin S.D., Yan C., Bornfeldt K.E., and Beavo J.A. Cyclic GMP phosphodiesterases and regulation of smooth muscle function. Circ. Res. 93 (2003) 280-291
33. Scatchard G. The attraction of proteins or small molecules and ions. Ann. N.Y. Acad. Sci. 51 (1949) 660-672
34. Schneider H.H., Schmiechen R., Brezinski M., and Seidler J. Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur. J. Pharmacol. 127 (1986) 105-115
35. Silver P.J., Hamel L.T., Perrone M.H., Bentley R.G., Bushover C.R., and Evans D.B. Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle. Eur. J. Pharmacol. 150 (1988) 85-94
36. Thompson W.J., and Appleman M.M. Multiple cyclic nucleotide phosphodiesterase activities from rat brain. Biochemistry 10 (1971) 311-316
37. Tucker J., and Fanta C.H. Integrative inflammation pharmacology: asthma. In: Golan D.E., Tashjian Jr. A.H., Armstrong E.J., Galanter J.M., Armstrong A.W., Arnaout R.A., and Rose H.S. (Eds). Principles of Pharmacology,The Pathophysiologic Basis of Drug Therapy (2005), Lippincott Williams & Wilkins, Philadelphia, PA 695-705
38. Ueda H., Yamazaki C., and Yamazaki M. Luteolin as an anti-inflammatory and anti-allergic constituent of Perilla frutescens. Biol. Pharm. Bull. 25 (2002) 1197-1202
39. Xagorari A., Papapetropoulos A., Mauromatis A., Economou M., Fotsis T., and Roussos C. Luteolin inhibits an endotoxin-stimulated phosphorylation cascade and proinflammatory cytokine production in macrophages. J. Pharmacol. Exp. Ther. 296 (2001) 181-187
40. 3H]-rolipram. J. Pharmacol. Exp. Ther. 305 (2003) 565-572
41. Ziyan L., Yongmei Z., Nan Z., Ning T., and Baolin L. Evaluation of the anti-inflammatory activity of luteolin in experimental animal models. Planta Med. 73 (2007) 221-226